摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

7-amino-1,3-dimethyl-5-(4-nitrophenyl)-2,4-dioxo-1,3,4,5-tetrahydro-2H-pyrano[2,3-d]pyrimidine-6-carbonitrile | 496971-17-6

中文名称
——
中文别名
——
英文名称
7-amino-1,3-dimethyl-5-(4-nitrophenyl)-2,4-dioxo-1,3,4,5-tetrahydro-2H-pyrano[2,3-d]pyrimidine-6-carbonitrile
英文别名
7-amino-5-(4-nitrophenyl)-1,3-dimethyl-2,4-dioxo-1,3,4,5-tetrahydro-2H-pyrano[2,3-d]pyrimidine-6-carbonitrile;7-amino-5-(4-nitrophenyl)-1,3-dimethyl-2,4-dioxo-2,3,4,5-tetrahydro-1H-pyrano[2,3-d]-pyrimidine-6-carbonitrile;7-amino-1,3-dimethyl-5-(4-nitrophenyl)-2,4-dioxo-5H-pyrano[2,3-d]pyrimidine-6-carbonitrile
7-amino-1,3-dimethyl-5-(4-nitrophenyl)-2,4-dioxo-1,3,4,5-tetrahydro-2H-pyrano[2,3-d]pyrimidine-6-carbonitrile化学式
CAS
496971-17-6
化学式
C16H13N5O5
mdl
——
分子量
355.31
InChiKey
UXTGFHYKPYXBFD-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    212-214 °C
  • 沸点:
    633.7±65.0 °C(Predicted)
  • 密度:
    1.58±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.8
  • 重原子数:
    26
  • 可旋转键数:
    1
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.19
  • 拓扑面积:
    146
  • 氢给体数:
    1
  • 氢受体数:
    7

反应信息

  • 作为反应物:
    描述:
    7-amino-1,3-dimethyl-5-(4-nitrophenyl)-2,4-dioxo-1,3,4,5-tetrahydro-2H-pyrano[2,3-d]pyrimidine-6-carbonitrile碘苯二乙酸三乙胺 作用下, 以 二氯甲烷 为溶剂, 反应 0.5h, 以88%的产率得到5,7-dimethyl-2-(4-nitrophenyl)-4,6,8-trioxo-5,7-diazaspiro[2.5]octane-1,1-dicarbonitrile
    参考文献:
    名称:
    吡喃并吡唑和吡喃并嘧啶二酮和路易斯酸分子内环丙烷化的螺环丙烷与螺环丙基吡唑啉酮的(3 + 2)环加成反应
    摘要:
    首先在温和的反应条件下,使用碘基苯(PhIO)或碘代苯二乙酸酯(PIDA)/分子碘(I 2)的组合,对吡喃并吡唑和吡喃并嘧啶-二酮衍生物进行强大的分子内环丙烷化反应,获得螺环丙基吡唑并酮和巴比妥酸酯。通过路易斯酸催化的合成的螺-环丙基吡唑啉酮与苯基异硫氰酸酯和苯并三腈的高非对映选择性(3 + 2)环加成反应,还证实了功能和立体化学多样化的新型螺并吡唑啉酮稠合的2-亚氨基噻吩和螺并吡咯啉酮稠合的吡咯啉支架。
    DOI:
    10.1021/acs.joc.7b00089
  • 作为产物:
    描述:
    1,3-二甲基-5-(4-硝基苯亚甲基)-2,4,6-(1H,3H,5H)嘧啶三酮丙二腈对氨基苯磺酸 作用下, 以 乙醇 为溶剂, 以90 %的产率得到7-amino-1,3-dimethyl-5-(4-nitrophenyl)-2,4-dioxo-1,3,4,5-tetrahydro-2H-pyrano[2,3-d]pyrimidine-6-carbonitrile
    参考文献:
    名称:
    乙醇水溶液中声化学合成烯醇化羰基及其类似物的亚苄基衍生物
    摘要:
    这项工作描述了在乙醇水溶液中使用有机催化剂高效、简洁、绿色地声化学合成烯醇化羰基的亚苄基衍生物,其中包括巴比妥酸衍生物、吡唑-5-酮和绕丹宁。该方法能够通过烯醇化羰基的直接 sp 3 C–H 烯化反应合成各种亚苄基衍生物。我们非常强调这些衍生物的合成实用性,并使用1 H-NMR 和13 C-NMR 光谱 (APT) 以及代表性化合物的 SC-XRD 研究来验证分子结构。 图形概要
    DOI:
    10.1007/s11164-023-05168-3
点击查看最新优质反应信息

文献信息

  • Effect of Liquid Glass Composition on the Catalytic Preparation of Pyrano[2,3-d]pyrimidine Derivatives
    作者:Mehdi Abaszadeh、Seyyed Jalal Roudbaraki、Majid Ghashang
    DOI:10.1080/00304948.2019.1600124
    日期:2019.5.4
    compounds containing at least one core moiety of pyrano[2,3-d]pyrimidine have received considerable attention in synthetic organic chemistry because of their potential as drugs and bioactive compounds. Pyrano[2,3-d]pyrimidines have attracted interest in medicine as antitumor, anti-hypertensive, antibacterial and antileishmanial drugs. Pyrano[2,3-d]pyrimidines have been produced by a number of methods. A
    本研究的主要目的是使用液态玻璃作为催化剂催化制备5-芳基-1,3,4,5-四氢2H-吡喃并[2,3-d]嘧啶-6-腈衍生物。所有反应均在水中回流条件下进行。作为进一步的目标,使用高速球磨 (HSBM) 技术研究了该过程。研究了液态玻璃成分和添加金属氧化物杂质的影响。最近,含有至少一个吡喃并[2,3-d]嘧啶核心部分的化合物因其作为药物和生物活性化合物的潜力而在合成有机化学中受到了相当大的关注。吡喃并[2,3-d]嘧啶作为抗肿瘤、抗高血压、抗菌和抗利什曼病药物在医学上引起了人们的兴趣。吡喃并[2,3-d]嘧啶已通过多种方法生产。可以获得对合成程序的完整审查和关于这些化合物的讨论。分子式为 Na2(SiO2)nO 的液态玻璃是一种硅酸钠水溶液,可通过 NaOH (25%) 与 SiO2 反应或通过将碳酸钠与二氧化硅熔化来制备。数十年来,液态玻璃一直被用作粘合剂和涂层剂。液态玻璃是一种无毒、耐热
  • The first urea-based ionic liquid-stabilized magnetic nanoparticles: an efficient catalyst for the synthesis of bis(indolyl)methanes and pyrano[2,3-<i>d</i>]pyrimidinone derivatives
    作者:Mohammad Ali Zolfigol、Roya Ayazi-Nasrabadi、Saeed Baghery
    DOI:10.1002/aoc.3428
    日期:2016.5
    of bis(indolyl)methane derivatives via the condensation reaction between 2‐methylindole and aldehydes at room temperature under solvent‐free conditions. Also, pyrano[2,3‐d]pyrimidinone derivatives were prepared in the presence of the nanomagnetic urea‐based catalyst by the one‐pot three‐component condensation reaction of 1,3‐dimethylbarbituric acid, aldehydes and malononitrile under solvent‐free conditions
    基于尿素的离子液体稳定在二氧化硅包覆的Fe 3 O 4磁性纳米颗粒上,Fe 3 O 4 @SiO 2 @(CH 2)3-尿素-SO 3H / HCl}是碱土中一种无与伦比的,平滑释放的尿素肥料,并通过傅立叶变换红外光谱,可见光和能量分散的X射线光谱,X射线衍射,扫描和透射电子显微镜,原子能对其进行了全面表征。力显微镜和热重分析。纳米结构催化剂是一种新型,绿色,高效的催化剂,它通过2-甲基吲哚与醛在室温下在无溶剂条件下的缩合反应用于合成双(吲哚基)甲烷衍生物。另外,吡喃并[2,3- d] pyrimidinone衍生物是在纳米磁性脲基催化剂存在下,在60°C无溶剂条件下,通过1,3-二甲基巴比妥酸,醛和丙二腈的单锅三组分缩合反应制备的。据我们所知,这是首次合成在二氧化硅包覆的Fe 3 O 4磁性纳米粒子上稳定的脲基离子液体的报告。因此,当前的工作可以在合理设计,合成和应用特定任务的基于肥料
  • Efficient Synthesis of New Pyrimido[5′,4′:5,6]pyrano[2,3-d]pyrimidine-2,4,6(1H,3H)-triones via the Tandem Intramolecular Pinner–Dimroth Rearrangement, and Their Antibacterial Activity
    作者:M. Asadian、A. Davoodnia、S. A. Beyramabadi
    DOI:10.1134/s1070363218120290
    日期:2018.12
    Synthesis of new 8-alkyl-5-aryl-1,3-dimethyl-5,7-dihydro-2H-pyrimido[5′,4′:5,6]pyrano[2,3-d]- pyrimidine-2,4,6(1H,3H)-triones by the high yield reaction of 7-amino-5-aryl-1,3-dimethyl-2,4-dioxo-1,3,4,5- tetrahydro-2H-pyrano[2,3-d]pyrimidine-6-carbonitriles with aliphatic carboxylic acids in the presence of POCl3 is presented. It is probable that synthesis of these new products proceeds via the tandem
    合成新的8-烷基-5-芳基-1,3-二甲基-5,7-二氢-2 H-嘧啶[5',4':5,6]吡喃并[2,3 - d ]-嘧啶-2 7-氨基-5-芳基-1,3-二甲基-2,4-二氧杂-1,3,4,5-四氢-2的高产率反应得到4,4,6 (1 H,3 H)-三酮提出了在POCl 3存在下具有脂肪族羧酸的H-吡喃并[2,3 - d ]嘧啶-6-腈。这些新产品的合成很可能是通过分子内Pinner-Dimroth重排进行的。产品经FT-IR,1 H和13 C NMR光谱表征,并评估其对革兰氏+ ve细菌(金黄色葡萄球菌)的抗菌活性。和表皮葡萄球菌)和革兰氏阴性细菌已经(大肠杆菌和绿脓杆菌使用盘扩散法)。
  • Synthesis, characterization and application of ZnFe<sub>2</sub>O<sub>4</sub>nanoparticles as a heterogeneous ditopic catalyst for the synthesis of pyrano[2,3-d] pyrimidines
    作者:Ardeshir Khazaei、Azam Ranjbaran、Fatemeh Abbasi、Marzieh Khazaei、Ahmad Reza Moosavi-Zare
    DOI:10.1039/c4ra16664g
    日期:——

    In the present work, ZnFe2O4nanopowder, as a highly efficient and heterogeneous catalyst, was prepared and fully characterized by IR, UV, XRD, EDX and SEM analysis.

    在目前的工作中,作为一种高效的非均相催化剂,ZnFe2O4纳米粉末通过红外、紫外、X射线衍射、能谱分析和扫描电子显微镜进行了全面表征。
  • SO<sub>3</sub>H-functionalized nano-MGO-D-NH<sub>2</sub>: Synthesis, characterization and application for one-pot synthesis of pyrano[2,3-<i>d</i>]pyrimidinone and tetrahydrobenzo[<i>b</i>]pyran derivatives in aqueous media
    作者:Heshmatollah Alinezhad、Mehrasa Tarahomi、Behrooz Maleki、Amirhassan Amiri
    DOI:10.1002/aoc.4661
    日期:2019.3
    of a magnetic graphene oxide (GO) nanohybrid and evaluated in the synthesis of tetrahydrobenzo[b]pyran and pyrano[2,3‐d]pyrimidinone derivatives. The GO/Fe3O4 (MGO) hybrid was prepared via an improved Hummers method followed by the covalent attachment of 1,4‐butanesultone with the amino group of the as‐prepared polyamidoamine‐functionalized MGO (MGO‐D‐NH2) to give double‐functionalized magnetic nanoparticles
    SO 3 H-官能化的纳米MGO-D-NH 2催化剂是通过磁性氧化石墨烯(GO)纳米杂化物的多官能化制备的,并在四氢苯并[ b ]吡喃和吡喃[2,3- d ]嘧啶酮衍生物。通过改进的Hummers方法制备GO / Fe 3 O 4(MGO)杂化物,然后将1,4-丁磺酸内酯与已制备的聚酰胺型胺官能化MGO(MGO-D-NH 2)得到双功能化的磁性纳米粒子作为催化剂。表征所制备的纳米颗粒以确认其合成并精确确定其理化性质。总之,就反应时间和产物产率而言,制备的催化剂显示出显着的可循环性和催化性能。希望这项研究的结果有助于开发新型的非均相催化剂,以显示出高性能并作为工业应用的优秀候选者。
查看更多

同类化合物

乙基7'-氨基-6-氟-2,2',4'-三羰基-1,1',2,2',3',4'-六氢螺[吲哚-3,5'-吡喃并[2,3-d]嘧啶]-6'-羧酸酯 7H-吡喃并[2,3-d]嘧啶-7-酮 7H-吡喃并[2,3-d]嘧啶 7,8-二氢-5H-吡喃并[4,3-D]嘧啶-2-胺 5H-吡喃并[4,3-d]嘧啶 5H-吡喃并[2,3-d]嘧啶 2H-吡喃并[2,3-d]嘧啶-6-甲腈,7-氨基-1,3,4,5-四氢-5-(4-甲氧苯基)-2,4-二羰基- 2,4-二氯-7,8-二氢-5H-吡喃[4,3-d]嘧啶 1H-吡喃并[3,4-d]嘧啶 1H-吡喃并[3,2-d]嘧啶 4-(4-methoxyaniline)-5-(phenyl)-8,9-dihydro-5H-chromeno[2,3-d]pyrimidin-6(7H)-one 4-cyclohexyl-2-phenyl-7,8-dihydro-6H-pyranol[3,2-d]pyrimidine 1,3-Bis(p-tolyl)-5-(2'-hydroxyphenyl)-7-methyl-4-oxo-1,2,3,4-tetrahydro-2-thioxo-5H-pyrano<2,3-d>pyrimidine 7,8-dihydro-3H-pyrano[4,3-d]pyrimidin-4(5H)-one 7-amino-2,3,4,5-tetrahydro-5-(3-hydroxyphenyl)-1,3-dimethyl-2,4-dioxo-1H-pyrano[2,3-d]pyrimidine-6-carbonitrile 3-benzyl-6,6,9-trimethyl-6a,7,8,9,10,10a-hexahydro-6H-isochromeno[3,4-d]pyrimidin-1-ol 7'-amino-1-ethyl-2,4'-dioxo-2'-thioxo-1',2',3',4'-tetrahydrospiro[indoline-3,5'-pyrano[2,3-d] pyrimidine]-6'-carbonitrile 7'-amino-2,4'-dioxo-2'-thioxo-1',2',3',4'-tetrahydro-2H-spiro[acenaphthylene-1,5'-pyrano[2,3-d]pyrimidine]-6'-carbonitrile (3-(((2-(4-(but-2-ynamido)-2-methyl-1H-indol-1-yl)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-4-yl)amino)methyl)phenyl)boronic acid 7-amino-5-(2,3-dimethoxyphenyl)-1,3-dimethyl-2,4-dioxo-2,3,4,5-tetrahydro-1H-pyrano[2,3-d]pyrimidine-6-carbonitrile 7'-amino-5-chloro-1',3'-dimethyl-2,2',4'-trioxo-1',2',3',4'-tetrahydrospiro[indoline-3,5'-pyrano[2,3-d]pyrimidine]-6'-carbonitrile 7-amino-5-(4-bromophenyl)-1,3-dimethyl-2,4-dioxo-1,3,4,5-tetrahydro-2H-pyrano[2,3-d]pyrimidine-6-carbonitrile 7-amino-5-(4-methoxyphenyl)-1,3-dimethyl-2,4-dioxo-1,3,4,5-tetrahydro-2H-pyrano[2,3-d]-pyrimidine-6-carbonitrile 7,8-dihydro-5H-pyrano[4,3-d]pyrimidine ethyl 2,8-dimethyl-10-phenyl-10H-pyrano[3,2-e][1,2,4]triazolo[1,5-c] pyrimidine-9-carboxylate ethyl 10-(4-methoxyphenyl)-2,8-dimethyl-10H-pyrano[3,2-e][1,2,4]triazolo[1,5-c] pyrimidine-9-carboxylate ethyl 3-{[3-(4-methoxyphenyl)isoxazol-5-yl]methyl}-2,7-dimethyl-4-oxo-5-(p-tolyl)-3,5-dihydro-4H-pyrano[2,3-d]pyrimidine-6-carboxylate 2-thioxo-2,3,7,8-tetrahydro-1H-pyrano[4.3-d]pyrimidin-4(5H)-one 7-amino-2,4-dioxo-5-(m-tolyl)-1,3,4,5-tetrahydro-2H-pyrano[2,3-d]pyrimidine-6-carbonitrile Ethyl 7-amino-5-(4-hydroxyphenyl)-2,4-dioxo-2,3,4,5-tetrahydro-1H-pyrano[2,3-d]pyrimidine-6-carboxylate 7-amino-5-(3-chlorophenyl)-2,4-dioxo-2,3,4,5-tetrahydro-1H-pyrano[2,3-d]pyrimidine-6-carbonitrile 7-amino-5-(2,4-di-chlorophenyl)-2,4-dioxo-2,3,4,5-tetrahydro-1H-pyrano[2,3-d]pyrimidine-6-carbonitrile 7-amino-5-(4-(dimethylamino)phenyl)-2,4-dioxo-2,3,4,5-tetrahydro-1H-pyrano[2,3-d]pyrimidine-6-carbonitrile Ethyl 7-amino-5-(3,4-dimethoxyphenyl)-2,4-dioxo-1,3,4,5-tetrahydro-2H-pyrano[2,3-d]pyrimidine-6-carboxylate 7-amino-5-(3,4-dimethoxyphenyl)-2,4-dioxo-2,3,4,5-tetrahydro-1H-pyrano[2,3-d]pyrimidine-6-carbonitrile ethyl-7-amino-5-(3-nitrphenyl)-2,4-dioxo-2,3,4,5-tetrahydro-1H-pyrano[2,3-d]pyrimidine-6-carboxylate Ethyl 7-amino-5-(4-nitrophenyl)-2,4-dioxo-1,3,4,5-tetrahydro-2H-pyrano[2,3-d]pyrimidine-6-carboxylate Ethyl 7-amino-5-(4-methylphenyl)-2,4-dioxo-1,3,4,5-tetrahydro-2H-pyrano[2,3-d]pyrimidine-6-carboxylate 7'-amino-5-chloro-2,2',4'-trioxo-1',2',3',4'-tetrahydrospiro[indoline-3,5'-pyrano[2,3-d]pyrimidine]-6'-carbonitrile 4-tert-butyl-2-phenyl-7,8-dihydro-6H-pyranol[3,2-d]pyrimidine 6-benzamido-2,3-dihydro-5-methyl-1,3-di(p-chlorophenyl)-2-thioxo-4H-pyrano[2,3-d]pyrimidine-4,7(1H)-dione 6-benzamido-2,3-dihydro-5-methyl-1,3-diphenyl-2-thioxo-4H-pyrano[2,3-d]pyrimidine-4,7(1H)-dione 4-phenylhexahydro-1H-pyrano[2,3-d]pyrimidin-2(8aH)-one 4-(4-methoxyphenyl)hexahydro-1H-pyrano[2,3-d]pyrimidin-2(8aH)-one 7-amino-1,3-dimethyl-2,4-dioxo-5-phenyl-1,3,4,5-tetrahydro-2H-pyrano[2,3-d]pyrimidine-6-carbonitrile 7'‑amino‑2,4′‑dioxo‑2′‑thioxo‑1′,2′,3′,4′‑tetrahydrospiro[indoline‑3,5'‑pyrano[2,3‑d]pyrimidine]‑6'‑carbonitrile 7-Amino-5-(1H-indol-3-yl)-2,4-dioxo-2,3,4,5-tetrahydro-1H-pyrano[2,3-d] pyrimidine-6-carbonitrile methyl 2-amino-5,7-dioxospiro[1'-methyl-3'H-indol-3',4-4H-5,6,7,8-tetrahydropyrano[2,3-d]pyramidine]-1'H-2'-one-3-carboxylate 7-benzyl-7-methyl-4-phenyl-3,4,7,8-tetrahydro-1H-pyrano[4,3-d]pyrimidine-2,5-dione 7,7-dimethyl-4-phenyl-2-thioxo-1,2,3,4,7,8-hexahydro-pyrano[4,3-d]pyrimidin-5-one